

## **OBI PHARMA, INC.**

### **Notice of 2025 First Extraordinary General Shareholders' Meeting (Summary Translation)**

- I. The 2025 First Extraordinary General Shareholders' Meeting (the "Meeting") will be convened at 1F Conference Room, Taipei Bioinnovation Park (No. 508, Section 7, Zhongxiao East Road, Nangang District, Taipei City 115, Taiwan) at 9:00 am on October 20, 2025. The agenda for the Meeting is as follows:
1. Report Items
    - (1) Status of the first half of 2025 Sound Operating Plan of the Company
  2. Discussion Items
    - (1) The Company proposed to conduct a capital reduction to offset accumulated losses.
  3. Extemporaneous Motions
- II. The company proposed to conduct a capital reduction to offset accumulated losses. Details of the proposed plan are as follows:  
On September 1, 2025, the Company's Board of Directors resolved to conduct a capital reduction to offset accumulated losses, and aims to improve the Company's financial structure, enhance net asset value, and strengthen operational fundamentals. Moving forward, the Company will focus on the development of next-generation antibody-drug conjugates (ADCs) and actively exploring early-stage licensing and global partnership opportunities.  
As of December 31, 2024, the Company reported accumulated losses of NT\$7,879,038,708. In accordance with relevant regulations, the Company will reduce its capital by NT\$1,315,796,870, canceling 131,579,687 outstanding common shares, and the capital reduction ratio is 50%. Meaning 500 shares will be canceled for every 1,000 shares held (i.e., shareholders will receive 500 new shares for every 1,000 original shares). The post-reduction paid-in capital will be NT\$1,315,796,870, with a par value of NT\$10 per share and a total of 131,579,687 shares outstanding.
- III. Under Article 165 of the Company Act, share transfer registration for the Company will be suspended from September 21, 2025, to October 20, 2025.
- IV. Under Article 172 of the Company Act, the Company shall list the convened matters and contents on MOPS (<https://mops.twse.com.tw>).
- V. Besides the announcement published in MOPS, please find the Notice of Attendance and Proxy Statement enclosed with this Meeting Notice. Kindly check and your presence is highly solicited. If you plan to attend the Meeting in person, please affix your signature or personal seal to the Sign-in Card and deliver it for registration or

submit it on the day of the Meeting. If you wish to appoint a proxy to attend the Meeting, please refer to the Proxy Statement instruction and return a folded Proxy Statement with information filled. Such Proxy Statement shall be delivered to the Company's securities agent, the Register and Transfer Agency division of MasterLink Securities Corporation, at least five (5) days before the Meeting so that a sign-in card can be issued to the proxy.

- VI. If any shareholder solicits proxies, the Company will publish a summary of such solicitation on the Securities and Futures Commission website (<http://free.sfi.org.tw>) before October 1, 2025. For shareholders who wish to make inquiries, please refer to the website for related information (ticker: 4174).
- VII. The period during which shareholders may cast electronic votes for the Meeting will be from October 5, 2025, to October 17, 2025. The shareholders may vote online for the Meeting by accessing the "shareholders e-services" page on the Taiwan Depository and Clearing Corporation website at <https://www.stockservices.tdcc.com.tw> and casting their votes based on the instructions on the website.
- VIII. The institution responsible for tallying and verifying the votes for the Company is the Register and Transfer Agency division of MasterLink Securities Corporation.
- IX. Kindly note and proceed accordingly.

Sincerely Yours  
The Board of Directors of OBI Pharma, Inc.